CTOs on the Move

Centric Health

www.centrichealth.ca

 
Centric Health`s vision is to be Canada`s premier healthcare company, providing innovative solutions centered on patients and healthcare professionals.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

LIFE Corporation

LIFE Corporation is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Electronic Waveform Lab Inc

Electronic Waveform Lab Inc is a Huntington Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Z-SC1 Biomedical

Z-SC1 Biomedical is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ForSight VISION5

ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.